Alvarez-Chaver Paula, Otero-Estévez Olalla, Páez de la Cadena María, Rodríguez-Berrocal Francisco J, Martínez-Zorzano Vicenta S
Paula Álvarez-Chaver, Unidad de Proteómica, Servicio de Determinación Estructural, Proteómica y Genómica, Centro de Apoyo Científico y Tecnológico a la Investigación, Universidad de Vigo, Campus As Lagoas-Marcosende, 36310 Vigo (Pontevedra), Spain.
World J Gastroenterol. 2014 Apr 14;20(14):3804-24. doi: 10.3748/wjg.v20.i14.3804.
Colorectal cancer (CRC) is the second most common cause of cancer-related deaths in Europe and other Western countries, mainly due to the lack of well-validated clinically useful biomarkers with enough sensitivity and specificity to detect this disease at early stages. Although it is well known that the pathogenesis of CRC is a progressive accumulation of mutations in multiple genes, much less is known at the proteome level. Therefore, in the last years many proteomic studies have been conducted to find new candidate protein biomarkers for diagnosis, prognosis and as therapeutic targets for this malignancy, as well as to elucidate the molecular mechanisms of colorectal carcinogenesis. An important advantage of the proteomic approaches is the capacity to look for multiple differentially expressed proteins in a single study. This review provides an overview of the recent reports describing the different proteomic tools used for the discovery of new protein markers for CRC such as two-dimensional electrophoresis methods, quantitative mass spectrometry-based techniques or protein microarrays. Additionally, we will also focus on the diverse biological samples used for CRC biomarker discovery such as tissue, serum and faeces, besides cell lines and murine models, discussing their advantages and disadvantages, and summarize the most frequently identified candidate CRC markers.
在欧洲和其他西方国家,结直肠癌(CRC)是癌症相关死亡的第二大常见原因,主要是因为缺乏经过充分验证、具有足够敏感性和特异性以在早期阶段检测该疾病的临床有用生物标志物。尽管众所周知CRC的发病机制是多个基因中突变的逐步积累,但在蛋白质组水平上了解得却少得多。因此,在过去几年中,已经进行了许多蛋白质组学研究,以寻找用于诊断、预后的新候选蛋白质生物标志物以及作为这种恶性肿瘤的治疗靶点,并阐明结直肠癌发生的分子机制。蛋白质组学方法的一个重要优势是能够在一项研究中寻找多种差异表达的蛋白质。本综述概述了最近的报告,这些报告描述了用于发现CRC新蛋白质标志物的不同蛋白质组学工具,如二维电泳方法、基于定量质谱的技术或蛋白质微阵列。此外,除了细胞系和小鼠模型外,我们还将关注用于CRC生物标志物发现的各种生物样本,如组织、血清和粪便,讨论它们的优缺点,并总结最常鉴定出的候选CRC标志物。